Dataset Information

Oncoxin-Viusid- Quality of life of patients with metastatic colorectal adenocarcinoma-adults-Phase II

ABSTRACT: Interventions: Experimental group: Oncoxin-Viusid An oral solution of Oncoxin (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and dinner aproximately during 29 weeks. It will be prescribed for a period of 2 weeks before start the Chemotherapy (CT) up to 3 weeks after finish it. The treatment with Oncoxin-Viusid will continue in the possible periods of time of suspension of the CT treatment due to toxicities attributable to it. The treatment will be administered continuously for approximately 29 weeks from the patient s inclusion in the study.;Dietary Supplements;Administration, Oral;Oncoxin viusid Primary outcome(s): Quality of life (Instruments: EORTC QLQ-C30 and colorectal cancer specific QLQ-CR29, The final score and that of each item of both scales will be collected). Measurement time: at baseline, 3 months and final evaluation (4 weeks after finished the last cycle of chemotherapy). Study Design: Allocation: N/A: single arm study. Masking: Open. Control group: Uncontrolled. Assignment: Single group. Purpose: Treatment

DISEASE(S): Metastatic Colorectal Adenocarcinoma,Gastrointestinal Diseases,Gastrointestinal Neoplasms,Rectal Diseases,Intestinal Diseases,Digestive System Diseases,Colorectal Neoplasms,Intestinal Neoplasms,Digestive System Neoplasms,Colonic Diseases

PROVIDER: 2571618 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:BACKGROUND: Protein undernutrition is prevalent mainly among elderly people, and it could develop diseases such as sarcopenia. Urinary metabolites may become biomarkers reflecting protein undernutrition, but this has been insufficiently investigated.OBJECTIVE: The purpose of this study was to identify novel urinary metabolites as biomarker candidates responsive to protein undernutrition.METHODS: Adult male Wistar rats were fed an AIN-93 M diet [14% casein, control (CT) diet] or an AIN-93 M-based isocaloric diet [5% casein, low protein (LP) diet] for 4 weeks. 1H nuclear magnetic resonance metabolomic analysis was performed on urine samples weekly and on plasma and liver samples at week 4 to identify metabolites that respond to protein undernutrition. Liver samples were also subjected to mRNA microarray and quantitative PCR analyses at week 4 to investigate alterations of the gene expressions responsive to protein undernutrition.RESULTS: Urinary taurine levels were significantly lower in the LP group than in the CT group (79.7% lower) at week 1, and remained constant until week 4. Hepatic taurine level and gene expression level of cysteine dioxygenase type 1, the rate-limiting enzyme for taurine biosynthesis, were also significantly lower in the LP group than in the CT group (81.1% and 32.5% lower, respectively). Urinary trimethylamine N-oxide (TMAO) levels were significantly higher in the LP group than in the CT group (49.7% higher) at week 2, and remained constant until week 4. Hepatic TMAO level was also higher in the LP group than in the CT group (81.2% higher). Hepatic gene expression levels of flavin-containing monooxygenase 1 and 5, the enzymes for TMAO biosynthesis, were also significantly higher in the LP group than in the CT group (61.6% and 311.8% higher, respectively).CONCLUSIONS: Urinary taurine and TMAO levels substantially respond to LP diet ingestion, and may act as non-invasive biomarker candidates to detect protein undernutrition.

Dataset Information

Oncoxin-Viusid- Quality of life of patients with metastatic colorectal adenocarcinoma-adults-Phase II

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure